Tech Company Financing Transactions
Neurogene Funding Round
Cormorant Asset Management, EcoR1 Capital Management and Redmile Group participated in a $68.5 million Series A funding round for Neurogene. The round was announced on 2/13/2019.
Transaction Overview
Company Name
Announced On
2/13/2019
Transaction Type
Venture Equity
Amount
$68,500,000
Round
Series A
Proceeds Purpose
With the funding announced today, Neurogene will advance multiple gene therapy programs into IND-enabling studies and clinical trials for patients with rare neurological diseases, invest in novel technologies for indications not addressed by traditional gene therapy approaches and establish a viral vector manufacturing facility.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
535 W 24th St. 5th Floor
New York, NY 10011
USA
New York, NY 10011
USA
Phone
Website
Email Address
Overview
Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rachel McMinn
Chief Medical Officer
Effie Albanis
Chief Scientific Officer
Stuart Cobb
President
Christine Mikail
VP - Operations
Ricardo Jimenez
VP - Operations
Arvind Sreedharan
Browse more venture capital transactions:
Prev: 2/13/2019: Evisort venture capital transaction
Next: 2/13/2019: Mode Analytics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs